領展(00823.HK)6億美元十年期票據以票息2.75釐定價
領展(00823.HK)宣佈,已成功爲其6億美元、於2032年到期的十年期高級票據發行定價,票息爲2.75釐,票據將於1月20日開始在港交所交易,是領展迄今發行規模最大、票息最低的美元債券。
領展行政總裁王國龍表示,縱然環球經濟環境仍然波動,很高興該等票據廣受衆多投資者的支持,並錄得超額認購,充份反映投資者高度認可集團的資本管理能力,並對集團具抗逆力的業務模式投下信心一票。
該等票據分別獲穆迪及標準普爾評爲「A2」及「A」評級。
此次發行的所得款項淨額將用作一般企業用途及營運資金,相信有助領展實踐「2025 願景」及推動未來增長計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.